Article Sidebar

PDF
Date Published: 26/05/2023
Abstract Views: 263
Views PDF: 144
DOI: https://doi.org/10.51298/vmj.v526i1B.5410
Issue
Vol. 526 No. 1B (2023)
Section
Các bài báo
How to Cite
Phạm , T. N. ., Đặng , V. E. ., & Lê, H. D. . (2023). CLINICAL FEATURE AND THE RESULT OF PSORIASIC OF PSORIASIC ERYTHRODERMA WITH METHOTREXATE. Vietnam Medical Journal, 526(1B). https://doi.org/10.51298/vmj.v526i1B.5410

CLINICAL FEATURE AND THE RESULT OF PSORIASIC OF PSORIASIC ERYTHRODERMA WITH METHOTREXATE

Thị Nga Phạm 1,, Văn Em Đặng 2, Hữu Doanh Lê3
1 Viet Tiep hospital
2 108 Military Central Hospital
3 National Hospital of Dermatology and Venereology

Main Article Content

Abstract

Objectives: To survey on some related factors, clinical characteristics and effectiveness of methotrexate treatment in patients with systemic erythrodermic psoriasis at the National Hospital of Dermatology from 01/01/2017 to 30/06/2019. Patients and methods: prospective, cross-sectional, self-comparative clinical trial. 112 patients, including 30 generalized erythrodermic psoriasis patients with no contraindications to methotrexate use and 30 healthy subjects similar in age and sex. Results: Male accounted for 87.2%, female accounted for 12.8%. Trigger factors: stress 83.3%, local infection 68.9%, no factor 19.6%, skin trauma 14.4%. Clinical symptoms: skin redness 94.6%, scaling 98.2%, itching 89.3%, edema 31.3%, keratosis pilaris 4.5%, fatigue 38.4%. Methotrexte was effective in treating RTIs: 50% good, 30% good, 13.33% moderate and 6.67% poor after 3 months of treatment. In which, PASI 67.7% and PASI-90: 3.34%, PASI-75: 40% and PASI-50: 43.33%. - Treatment results were not related to sex, age and disease age. The symptoms of fatigue, vomiting/nausea increased gradually over time of treatment after 12 weeks: fatigue 63.3%, vomiting/nausea: 33.3%. Conclusion: Treatment of erythrodermic psoriasis with Methotrexate gives good results and no serious side effects

Article Details

Keywords

systemic erythrodermic, clinical features, treatment

References

1. Đặng Văn Em. (2013). Bệnh vảy nến: Sinh bệnh học và chiến lược điều trị. NXB Y học: 23-57.
2. Collins P, Rogers S (1992). The efficacy of methotrexate in psoriasis – a review of 40 cases. Clin Exp Dermatol; 17(4):257–260.
3. Haustein UF, Rytter M (2000). Methotrexate in psoriasis: 26 years’ experience with low-dose long-term treatment. J Eur Acad Dermatol Venereol. ;14(5):382–388.
4. Khaled A, Ben Hamida M, Zeglaoui F, et al. (2012). Traitement du psoriasis par méthotrexate à des biothérapies: étude chez 21 patients tunisiens; Thérapie;67(1): 49-52.
5. Rosenbach M, Hsu S, Korman NJ, et al. (2010). Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol, 62(4): 655–662.
6. Singh RK, Lee KM, Ucmak D, et al. (2016). Erythrodermic psoriasis: pathophysiology and current treatment perspectives. Psoriasis: Targets and Therapy. 6: 93-104.
7. Van Dooren-Greebe RJ, Kuijpers AL, Mulder J et al (1994). Methotrexate revisited: effects of long-term treatment in psoriasis. Br J Dermatol. 1994;130(2): 204–210.